James Burke
Duke UMC · Jennerex Biotherapeutics · Billings Clinic (MCMRC network)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name James Burke as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:06 UTC. Open this list on ClinicalTrials.gov
- N/ANCT01730430 · Cerebrospinal Fluid (CSF) Biomarkers Alzheimer's Disease (AD) and Non-AD DementiasDuke University · completed · Alzheimer's Disease, Dementias · principal investigator
- Ph2NCT01636284 · A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver CancerJennerex Biotherapeutics · completed · Hepatocellular Carinoma · study director
- Ph1/Ph2NCT01394939 · Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal CarcinomaJennerex Biotherapeutics · completed · Colorectal Carcinoma, CRC · study director
- Ph2NCT01387555 · A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed SorafenibJennerex Biotherapeutics · completed · Hepatocellular Carcinoma, Liver Cancer, HCC · study director
- Ph2NCT00516841 · A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal CancerFacet Biotech · terminated · Ovarian Cancer, Peritoneal Neoplasms · principal investigator
- Ph1/Ph2NCT00429312 · A Study of Recombinant Vaccinia Virus to Treat Malignant MelanomaJennerex Biotherapeutics · completed · Melanoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:06 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 17 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- CLINICAL RESEARCH DEVELOPMENT COREP30AG028377 · NIA · DUKE UNIVERSITY · fiscal years 2006 to 2010 · $691,228 awarded in 2010Same name and institution; not confirmed by an ID
- MANIPULATION OF POLYGLUTAMINE-PROTEIN INTERACTIONSR01NS040540 · NINDS · DUKE UNIVERSITY · fiscal years 2000 to 2002 · $269,500 awarded in 2002Same name and institution; not confirmed by an ID
- EARLY GENES AND KINDLING DEVELOPMENTK08NS001533 · NINDS · DUKE UNIVERSITY · fiscal years 1991 to 1995 · $76,185 awarded in 1995Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:06 UTC. The ranking covers the 200 most relevant of 242 PubMed records, and a shared surname and initials can bring in a namesake. All 242 on PubMed
- The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection.N Engl J Med · 19921,240 citationsRCR 60.0
- Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.N Engl J Med · 2022835 citationsRCR 63.5
- Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.N Engl J Med · 2021663 citationsRCR 34.9
- Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.Nat Med · 2013660 citationsRCR 17.7
- 544 citationsRCR 16.0
- 494 citationsRCR 24.7
- Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.Nature · 2011466 citationsRCR 10.9
- Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.J Am Soc Nephrol · 2006408 citationsRCR 10.5
- Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.J Clin Oncol · 2017341 citationsRCR 10.7
- Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.N Engl J Med · 2024301 citationsRCR 35.7